Tsang G, O'Brien P, Robertson R, Hamilton C, Wratten C, Denham J
Department of Radiation Oncology, Newcastle Mater Hospital, Newcastle, New South Wales, Australia.
Australas Radiol. 2004 Sep;48(3):371-5. doi: 10.1111/j.0004-8461.2004.01321.x.
Prolonged waiting times for radiotherapy have resulted in many centres assigning priorities to various patient or diagnostic groups. A high risk of progression on a waiting list is one factor that would reasonably influence the priority. The present descriptive study of 27 patients with Merkel cell carcinoma (MCC) found that a median wait of 24 days for radiotherapy is associated with a high risk of progression. Eleven (41%) of 27 patients developed progressive disease, including five (45%) of 11 patients waiting for adjuvant radiotherapy. Patients treated adjuvantly also had longer waiting times prior to their initial radiotherapy consultation (median 41 days), which may have contributed to the rate of progression. Merkel cell carcinoma is an aggressive but curable malignancy and appropriate management should include efforts to minimize all potential delays prior to the commencement of radiotherapy.
